OQL025

OQL025 is a first-in-disease topical small molecule drug developed by OnQuality Pharmaceuticals for the treatment of moderate to severe acneiform rash in patients receiving epidermal growth factor receptor (EGFR) inhibitors. Acneiform rash is a common and sometimes severe side effect of EGFR inhibitor therapy, which is widely used in cancer treatment. The condition can negatively impact quality of life and may require dose reduction or discontinuation of anticancer therapy. OQL025 acts as a Janus kinase (JAK) inhibitor and is designed to selectively target key pathways involved in the development of EGFR inhibitor-induced rashes, with low systemic exposure due to its topical formulation[1][2][3][5][6].